2-甲磺酰氨基苯胺 | 37073-18-0

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲磺酰氨基苯胺
• 中文别名: 2-甲磺酰胺基苯胺
• 英文名称: N-(2-aminophenyl)methanesulfonamide
• CAS: 37073-18-0
• 化学式: C₇H₁₀N₂O₂S
• 分子量: 186.235
• InChiKey: BGPNDOBOLHJJEE-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C
• 沸点：
  340.1±44.0 °C(Predicted)
• 密度：
  1.408±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为室温、避光且在惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Methylsulfonamido)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Methylsulfonamido)aniline
CAS number: 37073-18-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2S
Molecular weight: 186.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲磺酰氨基苯胺 在 碘苯二乙酸 、 potassium carbonate 、 sodium sulfate 、 palladium dichloride 作用下， 以 甲苯 为溶剂， 反应 40.0h， 生成 ethyl 1-methylsulfonyl-1H-benzo[d]imidazole-2-carboxylate
  参考文献：
  名称：

  钯催化的亚胺的分子内磺酰胺化/氧化：获得多功能苯并咪唑

  摘要：

  在室温下用氯化钯（II）/（二乙酰氧基碘）苯和碳酸钾处理后，O-磺酰胺基苯亚胺进行分子内磺酰胺化/氧化，以生成1,2-二取代的苯并咪唑。在温和条件下，苯并咪唑2位的取代基范围可以扩展到烷基，芳基，烯基，酰基和酯官能团。

  DOI：

  10.1002/adsc.201100370
• 作为产物：
  描述：

  2-硝基苯胺 在 吡啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 26.0h， 生成 2-甲磺酰氨基苯胺
  参考文献：
  名称：

  [EN] TYK2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。

  公开号：

  WO2018075937A1

文献信息

• [EN] PYRROLOPYRIMIDINES AS FAK AND ALK INHIBITERS FOR TREATMENT OF CANCERS AND OTHER DISEASES<br/>[FR] PYRROLOPYRIMIDINES À TITRE D'INHIBITEURS DE FAK ET D'ALK POUR LE TRAITEMENT DES CANCERS ET AUTRES MALADIES
  申请人：ABBOTT LAB

  公开号：WO2012045195A1

  公开（公告）日：2012-04-12

  Disclosed are compounds which inhibit the activity of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), compositions containing the compounds, and methods of treating diseases during which FAK and ALK are expressed. The diseases are, for example, cancers.

  揭示了抑制焦点粘附激酶（FAK）和间变性淋巴瘤激酶（ALK）活性的化合物，含有这些化合物的组合物，以及治疗在其中FAK和ALK表达的疾病的方法。这些疾病例如包括癌症。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2015051241A1

  公开（公告）日：2015-04-09

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本发明描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及用于治疗与激酶活性相关的疾病和状况的化合物、药物组合物和方法，包括PI3激酶活性。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Schering Corporation

  公开号：US20040106794A1

  公开（公告）日：2004-06-03

  There are disclosed compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。
• Discovery and characterization of an acridine radical photoreductant
  作者：Ian A. MacKenzie、Leifeng Wang、Nicholas P. R. Onuska、Olivia F. Williams、Khadiza Begam、Andrew M. Moran、Barry D. Dunietz、David A. Nicewicz

  DOI：10.1038/s41586-020-2131-1

  日期：2020.4.2

  copper5,6. Although various closed-shell organic molecules have been shown to behave as competent electron-transfer catalysts in photoredox reactions, there are only limited reports of PET reactions involving neutral organic radicals as excited-state donors or acceptors. This is unsurprising because the lifetimes of doublet excited states of neutral organic radicals are typically several orders of magnitude

  光致电子转移 (PET) 是一种现象，化学物质对光的吸收为电子转移反应提供能量驱动力1,2,3,4. 这种机制与许多化学领域相关，包括自然和人工光合作用、光伏和光敏材料的研究。近年来，光氧化还原催化领域的研究使 PET 能够用于催化生成中性和带电的有机自由基物种。这些技术使以前无法实现的化学转化成为可能，并已广泛用于学术和工业环境。这种反应通常由吸收可见光的有机分子或钌、铱、铬或铜的过渡金属配合物催化5,6. 尽管各种闭壳有机分子已被证明在光氧化还原反应中充当有效的电子转移催化剂，但涉及中性有机自由基作为激发态供体或受体的 PET 反应的报道有限。这并不奇怪，因为中性有机自由基的双重激发态的寿命通常比已知的过渡金属光氧化还原催化剂的单重激发态寿命短几个数量级7,8,9,10,11。在这里，我们记录了最大激发态氧化电位为 -3.36 伏的中性吖啶自由基与饱和甘汞电极的发现、表征和反应性，后者
• [EN] THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS<br/>[FR] THIADIAZOLEDIOXYDES ET THIADIAZOLEOXIDES CONVENANT COMME LIGANDS DES RECEPTEURS DES CXC- ET CC-CHIMIOKINES
  申请人：PHARMACOPEIA INC

  公开号：WO2004033440A1

  公开（公告）日：2004-04-22

  Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

  披露了公式（IA）的新颖化合物以及其中医药可接受的盐和溶剂化物。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还披露了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心脏再灌注损伤、急性疼痛、急性和慢性炎症性疼痛，以及使用公式（IA）的化合物的神经性疼痛。